Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis-Reference-Cited by-同舟云学术

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis

Published:2015-11-18 Issue:2 Volume:172 Page:246-254
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bishton Mark J.¹,Hughes Simon²,Richardson Faith¹,James Eleanor³,Bessell Eric³,Sovani Vishakha⁴,Ganatra Rakesh²,Haynes Andrew P.⁵,McMillan Andrew K.¹,Fox Christopher P.¹

Affiliation:

1. Department of Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham UK

2. Department of Radiology; Nottingham University Hospitals NHS Trust; Nottingham UK

3. Department of Clinical Oncology; Nottingham University Hospitals NHS Trust; Nottingham UK

4. Department of Histopathology; Nottingham University Hospitals NHS Trust; Nottingham UK

5. Department of Medicine; Kings Mill Hospital; Sutton-in-Ashfield UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13831/fullpdf

Reference25 articles.

1. Rituximab and CODOX-M/IVAC without stem cell transplantation for poor risk diffuse large B cell lymphoma (IPI3-5) and Burkitts lymphoma is feasible and gives a high response rate: preliminary results of a phase 2 UK National Cancer Research Institute Trial;Ardeshna;Blood,2013

2. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group;Barrington;Journal of Clinical Oncology,2014

3. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

4. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

5. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab;Fayad;Journal of Clinical Oncology,2013

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients;Frontiers in Oncology;2024-06-05

2. Значение ПЭТ, совмещенной с КТ, при диффузной В-крупноклеточной лимфоме: история вопроса, эволюция представлений и современные возможности метода (обзор литературы);Clinical Oncohematology;2024-02-20

3. The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2024-01-21

4. Integration of PET in DLBCL;Seminars in Hematology;2023-12

5. PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B‑cell lymphoma patients;2023-11-07